|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-7-30
|
|
pubmed:abstractText |
Hepatitis B immune globulins (HBIG) in combination with nucleos(t)ide analogues (NA) are effectively used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, associated treatment costs for HBIG are exceedingly high.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-10094978,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-10915163,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-10965962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-10965963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-11084061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-11093723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-11451173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-11788930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-12362302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-12829990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-12971953,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-14509525,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-15110584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-15114086,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-15382222,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-15973718,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-16447195,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-17318855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-17383422,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-17553144,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-17958641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-18383078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-18825721,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-18825722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-18925641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-8247035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-9270768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20598161-9696028
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-230X
|
|
pubmed:author |
pubmed-author:BihlFlorianF,
pubmed-author:CastelliDamianoD,
pubmed-author:CernyAndreasA,
pubmed-author:Di GiammarinoLorianaL,
pubmed-author:GiostraEmilianoE,
pubmed-author:GurtnerVaninaV,
pubmed-author:HadengueAntoineA,
pubmed-author:MajnoPietroP,
pubmed-author:MenthaGillesG,
pubmed-author:MichelMartineM,
pubmed-author:Pizzi-BosmanLoredanaL,
pubmed-author:RussmannStefanS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
71
|
|
pubmed:meshHeading |
pubmed-meshheading:20598161-Adult,
pubmed-meshheading:20598161-Antiviral Agents,
pubmed-meshheading:20598161-Cost-Benefit Analysis,
pubmed-meshheading:20598161-Drug Therapy, Combination,
pubmed-meshheading:20598161-Female,
pubmed-meshheading:20598161-Follow-Up Studies,
pubmed-meshheading:20598161-Hepatitis B,
pubmed-meshheading:20598161-Hepatitis B Antibodies,
pubmed-meshheading:20598161-Humans,
pubmed-meshheading:20598161-Immunoglobulins,
pubmed-meshheading:20598161-Liver Transplantation,
pubmed-meshheading:20598161-Male,
pubmed-meshheading:20598161-Middle Aged,
pubmed-meshheading:20598161-Plasma,
pubmed-meshheading:20598161-Recurrence,
pubmed-meshheading:20598161-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation.
|
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, University Hospital of Geneva, Switzerland. f.bihl@mac.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
